Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine - Biologic Drug Details

Summary for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine

Recent Clinical Trials for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1

See all diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory of Diphtheria, Tetanus, and Pertussis Vaccines

Introduction

The diphtheria, tetanus, and pertussis (DTP) vaccine market is a crucial segment within the global vaccine industry, driven by the need to protect against these life-threatening diseases. This article delves into the market dynamics, financial trajectory, and key factors influencing the growth of the DTP vaccine market.

Market Size and Growth

The DTP vaccine market has been experiencing steady growth, driven by increasing demand for combination vaccines. As of 2019, the market was valued at $4,758.8 million and is projected to reach $7,054.4 million by 2027, with a Compound Annual Growth Rate (CAGR) of 5.1% during the forecast period[1].

Product Segments

The DTP vaccine market is segmented into various product types, with the DTaP (diphtheria, tetanus, and acellular pertussis) vaccine holding the dominant position. DTaP vaccines are preferred due to their efficacy and lower risk of side effects compared to whole-cell pertussis vaccines. The market is also seeing a rise in demand for tetravalent and pentavalent combination vaccines, which include additional protections against diseases such as poliomyelitis and Haemophilus influenzae type b[1].

Combination Vaccines

Combination vaccines like Pentacel, which protects against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b, are gaining traction. These vaccines offer the convenience of administering multiple immunizations in a single dose, reducing the number of injections needed and improving compliance with vaccination schedules[3][5].

Age Group Segmentation

The market is segmented into pediatric and adult vaccines. The pediatric segment dominates due to the high demand for DTP vaccines among infants and young children. Infants worldwide are required to receive three doses of DTP vaccine to protect against these diseases, according to WHO norms. However, the adult segment is also expected to show significant growth due to the increasing incidence of infectious diseases among adults[1].

Regional Analysis

Geographically, the DTP vaccine market is analyzed across North America, Europe, Asia-Pacific, and Latin America, Middle East, and Africa (LAMEA). North America held the highest market share in 2019 and is expected to maintain its lead throughout the forecast period. The Asia-Pacific region is anticipated to witness the highest growth rate, driven by increasing demand for DTP vaccines, growing awareness of newer technologies, and rising population awareness[1].

End Users

Hospitals are the dominant end users of DTP vaccines, followed by clinics and other healthcare facilities. The market value of DTP vaccines in hospitals is expected to continue growing due to the high volume of vaccinations administered in these settings[1].

Key Drivers

Several factors are driving the growth of the DTP vaccine market:

• Government and Non-Government Initiatives: Increased funding and initiatives by organizations like GAVI (Global Alliance for Vaccines and Immunizations) have boosted the development and distribution of DTP vaccines.
• Rising Awareness: Growing awareness among people about the importance of vaccinations has led to higher demand for DTP vaccines.
• Research and Development: Continuous R&D efforts by pharmaceutical companies to enhance vaccine efficacy and safety are driving market growth[1].

Challenges

Despite the growth, the market faces several challenges:

• High Development Costs: The high cost of vaccine development is a significant barrier.
• Inadequate Access: Limited access to vaccines in underdeveloped countries restricts market growth.
• Side Effects: Although rare, serious side effects from the pertussis component of the vaccine can be a concern[1][2].

Market Players

Major players in the DTP vaccine market include GlaxoSmithKline plc (GSK) and Sanofi, which hold significant market shares. These companies are investing heavily in R&D to improve vaccine technology and expand their product portfolios[1].

Financial Trajectory

The financial trajectory of the DTP vaccine market is positive, with a steady increase in market value. The market's growth is supported by increasing healthcare expenditure and initiatives to enhance vaccine R&D. The CAGR of 5.1% indicates a stable and growing market over the forecast period[1].

Emerging Markets

Emerging markets offer lucrative opportunities for key market players. The growing population and increasing awareness about vaccinations in these regions are expected to drive market growth in the coming years[1].

Combination Vaccines Market Outlook

The broader combination vaccines market, which includes DTP vaccines, is also experiencing significant growth. The global combination vaccines market is valued at $4.56 billion in 2022 and is predicted to reach $10.11 billion by 2031, growing at a CAGR of 9.5%[4].

Conclusion

The DTP vaccine market is driven by a combination of factors including government initiatives, rising awareness, and continuous R&D. Despite challenges such as high development costs and inadequate access, the market is expected to grow steadily. The dominance of DTaP vaccines and the rise of combination vaccines like Pentacel are key trends shaping the market.

Key Takeaways

• The DTP vaccine market is projected to reach $7,054.4 million by 2027.
• DTaP vaccines hold the dominant position in the market.
• Combination vaccines are gaining traction due to their convenience and efficacy.
• The pediatric segment dominates the market, but the adult segment is expected to grow.
• North America leads the market, while Asia-Pacific is expected to witness the highest growth rate.
• High development costs and inadequate access are significant challenges.

FAQs

Q: What is the expected market size of the DTP vaccine market by 2027? A: The DTP vaccine market is expected to reach $7,054.4 million by 2027[1].

Q: Which segment holds the dominant position in the DTP vaccine market? A: The DTaP vaccine segment holds the dominant position in the DTP vaccine market[1].

Q: What are the key drivers of the DTP vaccine market growth? A: Key drivers include government and non-government initiatives, rising awareness, and continuous R&D efforts[1].

Q: Which regions are expected to witness significant growth in the DTP vaccine market? A: North America is expected to maintain its lead, while the Asia-Pacific region is anticipated to witness the highest growth rate[1].

Q: What are the challenges faced by the DTP vaccine market? A: High development costs and inadequate access to vaccines in underdeveloped countries are significant challenges[1].

Sources

1. Allied Market Research - Diphtheria, Pertussis, and Tetanus (DTP) Vaccine Market
2. Mayo Clinic - Diphtheria, tetanus, acellular pertussis, polio, hib vaccine
3. FDA - Pentacel
4. InsightAce Analytic - Combination Vaccines Market Scope, Size, Share and Forecast to 2031
5. Pentacel - DTaP-IPV/ Hib Vaccination for Kids | Pentacel® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine)

Last updated: 2024-12-18